Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.
Video navigation menu
- What has been the standard of care to prevent progression of CKD? 00:37
- Outcome trials for CV safety in high-risk T2DM 01:50
- Renal outcomes of SGLT2 inhibitor trials 04:40
- Summary and recommendations 07:57
This lecture by prof. Rajiv Agarwal was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence" held during ERA-EDTA 2019 in Budapest, Hungary.
Rajiv Agarwal, MD, MBBS, FASN is Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
This is available as accredited online CME for members. Click the button below to enroll:Enroll